San Diego, CA – January 10st, 2018 – Avineuro Pharmaceuticals, Inc. reported today promising results of clinical Phase Ib trials on AVN-101, an orally bioavailable and safe multi-target drug candidate for the treatment of CNS diseases associated with memory loss, cognitive dysfunction, neurodegeneration, depression, and general anxiety. Patients tolerated AVN-101 well in a wide range of […]

Avineuro Completed Phase II Clinical Study Of AVN-211, A Selective 5-HT6 Receptor Antagonist Avineuro LLC announced completion of phase II pilot clinical study of AVN-211, a proprietary orally-bioavailable molecule of a 5-HT6 receptor antagonist. In a multicenter double-blind randomized placebo-controlled pilot study of efficacy and safety of AVN-211 for amplifying the effects of antipsychotic drugs […]

July 1, 2015. Avineuro LLC announced completion of phase II pilot clinical study of AVN-211, a proprietary orally-bioavailable molecule of a 5-HT6 receptor antagonist. In a multicenter double-blind randomized placebo-controlled pilot study of efficacy and safety of AVN-211 for amplifying the effects of antipsychotic drugs in patients with schizophrenia in a condition of incomplete remission […]

San Diego, CA – July 15th, 2013 – Avineuro Pharmaceuticals, Inc. announced today an initiation of Phase 2b clinical studies of AVN-211, the best in-class, selective small molecule antagonist of 5-HT6 receptor for treatment of Schizophrenia. Earlier Avineuro Pharmaceuticals, Inc. reported positive top-line results from a Phase 2a clinical trial in schizophrenia patients stabilized on […]

San Diego, CA – February 21st, 20011 – Avineuro Pharmaceuticals, Inc. reported today positive top-line results from a Phase 2a clinical proof of concept trial to assess AVN-211 as an augmentation therapy to improve cognition in schizophrenia patients. In a double blind trial in 50 patients stabilized on an atypical antipsychotic therapy, AVN-211 met the […]